JP2026026092A5 - - Google Patents
Info
- Publication number
- JP2026026092A5 JP2026026092A5 JP2025184688A JP2025184688A JP2026026092A5 JP 2026026092 A5 JP2026026092 A5 JP 2026026092A5 JP 2025184688 A JP2025184688 A JP 2025184688A JP 2025184688 A JP2025184688 A JP 2025184688A JP 2026026092 A5 JP2026026092 A5 JP 2026026092A5
- Authority
- JP
- Japan
- Prior art keywords
- cov
- fraction
- glycoprotein
- quillaja saponaria
- saponaria molina
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (18)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062966271P | 2020-01-27 | 2020-01-27 | |
| US62/966,271 | 2020-01-27 | ||
| US202062976858P | 2020-02-14 | 2020-02-14 | |
| US62/976,858 | 2020-02-14 | ||
| US202062983180P | 2020-02-28 | 2020-02-28 | |
| US62/983,180 | 2020-02-28 | ||
| US202063048945P | 2020-07-07 | 2020-07-07 | |
| US63/048,945 | 2020-07-07 | ||
| US202063051706P | 2020-07-14 | 2020-07-14 | |
| US63/051,706 | 2020-07-14 | ||
| US202063054182P | 2020-07-20 | 2020-07-20 | |
| US63/054,182 | 2020-07-20 | ||
| US16/997,001 | 2020-08-19 | ||
| US16/997,001 US10953089B1 (en) | 2020-01-27 | 2020-08-19 | Coronavirus vaccine formulations |
| US202063129392P | 2020-12-22 | 2020-12-22 | |
| US63/129,392 | 2020-12-22 | ||
| JP2022545141A JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
| PCT/US2021/015220 WO2021154812A1 (en) | 2020-01-27 | 2021-01-27 | Coronavirus vaccine formulations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545141A Division JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2026026092A JP2026026092A (ja) | 2026-02-16 |
| JP2026026092A5 true JP2026026092A5 (enExample) | 2026-03-10 |
Family
ID=77079351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545141A Active JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
| JP2025184688A Pending JP2026026092A (ja) | 2020-01-27 | 2025-10-31 | コロナウイルスワクチン製剤 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022545141A Active JP7792339B2 (ja) | 2020-01-27 | 2021-01-27 | コロナウイルスワクチン製剤 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230070886A1 (enExample) |
| EP (1) | EP4097123A4 (enExample) |
| JP (2) | JP7792339B2 (enExample) |
| KR (1) | KR20220141302A (enExample) |
| CN (1) | CN115720581A (enExample) |
| AU (1) | AU2021214064A1 (enExample) |
| BR (1) | BR112022014830A2 (enExample) |
| CA (1) | CA3165371A1 (enExample) |
| GB (1) | GB2610070A (enExample) |
| IL (1) | IL295142A (enExample) |
| MX (1) | MX2022009167A (enExample) |
| TW (1) | TW202142555A (enExample) |
| WO (1) | WO2021154812A1 (enExample) |
| ZA (1) | ZA202401922B (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10953089B1 (en) | 2020-01-27 | 2021-03-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| WO2021249116A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Coronavirus vaccine compositions, methods, and uses thereof |
| WO2021249011A1 (en) | 2020-06-10 | 2021-12-16 | Sichuan Clover Biopharmaceuticals, Inc. | Hiv vaccine compositions, methods, and uses thereof |
| WO2022041760A1 (en) | 2020-08-31 | 2022-03-03 | Sichuan Clover Biopharmaceuticals, Inc. | Methods and compositions for purification of trimeric fusion proteins |
| MX2023013081A (es) * | 2021-05-05 | 2024-01-15 | Novavax Inc | Composiciones de coronavirus e influenza y métodos para utilizarlas. |
| CN113773372B (zh) * | 2021-08-15 | 2024-08-02 | 北京科兴中维生物技术有限公司 | 重组蛋白及其制备方法和应用 |
| CN116041448B (zh) * | 2021-08-26 | 2025-05-13 | 江苏瑞科生物技术股份有限公司 | 新型冠状病毒免疫原性物质、其制备方法和应用 |
| EP4436984A1 (en) * | 2021-11-24 | 2024-10-02 | Flagship Pioneering Innovations VI, LLC | Coronavirus immunogen compositions and their uses |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US20250025549A1 (en) * | 2021-11-30 | 2025-01-23 | Novavax, Inc. | Coronavirus vaccine formulations |
| CN114031675B (zh) * | 2022-01-10 | 2022-06-07 | 广州市锐博生物科技有限公司 | 基于SARS-CoV-2的S蛋白的疫苗和组合物 |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| EP4709741A1 (en) * | 2023-05-12 | 2026-03-18 | Icosavax, Inc. | Coronavirus spike glycoprotein receptor binding domains and uses thereof |
| US20250109187A1 (en) | 2023-09-28 | 2025-04-03 | Novavax, Inc. | ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1508615A1 (en) * | 2003-08-18 | 2005-02-23 | Amsterdam Institute of Viral Genomics B.V. | Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnostics |
| EP2478760A1 (en) * | 2005-05-10 | 2012-07-25 | Monsanto Technology LLC | Genes and uses for plant improvement |
| PL2370099T3 (pl) * | 2008-12-09 | 2016-10-31 | Zmodyfikowane białka F RSV i sposoby ich zastosowania | |
| RU2014117068A (ru) * | 2011-09-30 | 2015-11-10 | Новавакс, Инк. | Вакцина на основе рекомбинантных наночастиц f из rsv против респираторно-синцитиального вируса |
| BR112016006122B1 (pt) * | 2013-09-19 | 2023-11-14 | Novavax, Inc | COMPOSIÇÃO IMUNOGÊNICA COMPREENDENDO UMA NANOPARTÍCULA DO CORONAVÍRUS DA SÍNDROME RESPIRATÓRIA DO ORIENTE MÉDIO (MERS-CoV) |
| CA2996007A1 (en) * | 2015-09-03 | 2017-03-09 | Novavax, Inc. | Vaccine compositions having improved stability and immunogenicity |
| WO2017161151A1 (en) * | 2016-03-16 | 2017-09-21 | Novavax, Inc. | Vaccine compositions containing modified zika virus antigens |
| US10960070B2 (en) * | 2016-10-25 | 2021-03-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Prefusion coronavirus spike proteins and their use |
| EP3595676A4 (en) * | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| CN111499692B (zh) * | 2020-06-16 | 2020-12-04 | 国家纳米科学中心 | 靶向新型冠状病毒covid-19的多肽及其应用 |
-
2021
- 2021-01-27 US US17/795,337 patent/US20230070886A1/en active Pending
- 2021-01-27 TW TW110103013A patent/TW202142555A/zh unknown
- 2021-01-27 KR KR1020227029337A patent/KR20220141302A/ko active Pending
- 2021-01-27 EP EP21747453.5A patent/EP4097123A4/en active Pending
- 2021-01-27 IL IL295142A patent/IL295142A/en unknown
- 2021-01-27 AU AU2021214064A patent/AU2021214064A1/en active Pending
- 2021-01-27 JP JP2022545141A patent/JP7792339B2/ja active Active
- 2021-01-27 GB GB2212336.8A patent/GB2610070A/en not_active Withdrawn
- 2021-01-27 CN CN202180021579.8A patent/CN115720581A/zh active Pending
- 2021-01-27 BR BR112022014830A patent/BR112022014830A2/pt unknown
- 2021-01-27 CA CA3165371A patent/CA3165371A1/en active Pending
- 2021-01-27 MX MX2022009167A patent/MX2022009167A/es unknown
- 2021-01-27 WO PCT/US2021/015220 patent/WO2021154812A1/en not_active Ceased
-
2024
- 2024-03-07 ZA ZA2024/01922A patent/ZA202401922B/en unknown
-
2025
- 2025-10-31 JP JP2025184688A patent/JP2026026092A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2026026092A5 (enExample) | ||
| AU765824B2 (en) | Vaccines | |
| AU766635B2 (en) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant | |
| Almeida et al. | Nasal delivery of vaccines | |
| JP2023512648A5 (enExample) | ||
| JP2019526580A5 (enExample) | ||
| JP2010500399A5 (enExample) | ||
| US20150064216A1 (en) | Dsrnas as influenza virus vaccine adjuvants or immuno-stimulants | |
| US20040047882A1 (en) | Adjuvant for vaccines | |
| JP2024516309A5 (enExample) | ||
| CN112439058A (zh) | 基于外泌体为载体的重组新型冠状病毒纳米疫苗方法 | |
| JP7618632B2 (ja) | 経鼻ｂ型肝炎ワクチン組成物およびその製造方法 | |
| US20240261392A1 (en) | Compositions and methods to increase coronavirus immune response | |
| WO1998046263A1 (en) | Saponin adjuvants in combination with dna vaccination | |
| EP1987840B1 (en) | Prime-boost vaccine for the protection of equines against viral infection | |
| WO2023159082A2 (en) | Nanotechnology based intranasal vaccine for covid-19 comprising chitosan | |
| Udaya Kumar et al. | Nasal vaccine as a booster shot: a viable solution to restrict pandemic? | |
| WO2023159081A2 (en) | Nanotechnology based intranasal vaccine for covid-19 | |
| RU2023126867A (ru) | Вакцинные составы против коронавируса | |
| AU2013206335B2 (en) | dsRNAs as influenza virus vaccine adjuvants or immuno-stimulants | |
| Verges | World Vaccine Congress Europe 2017. Barcelona, Spain-October 10-12, 2017 | |
| ZA200202268B (en) | Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one non-ionic surfactant. |